OptimizeRx (NASDAQ:OPRX) Price Target Raised to $11.00

OptimizeRx (NASDAQ:OPRX) had its target price lifted by research analysts at Citizens Jmp from $9.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price indicates a potential upside of 25.28% from the company’s current price.

Several other equities research analysts also recently issued reports on OPRX. Stifel Nicolaus set a $12.00 price objective on OptimizeRx in a research note on Thursday. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. UBS Group set a $11.00 target price on shares of OptimizeRx in a research note on Friday. Weiss Ratings restated a “sell (d)” rating on shares of OptimizeRx in a research note on Tuesday. Finally, Lake Street Capital dropped their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.43.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $8.78 on Friday. OptimizeRx has a one year low of $4.54 and a one year high of $22.25. The stock has a fifty day moving average of $6.04 and a 200-day moving average of $6.72. The company has a market capitalization of $164.71 million, a PE ratio of 38.18 and a beta of 1.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. The business had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a return on equity of 9.52% and a net margin of 4.66%. As a group, equities analysts anticipate that OptimizeRx will post 0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

Several large investors have recently added to or reduced their stakes in OPRX. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the second quarter valued at $44,000. BNP Paribas Financial Markets lifted its holdings in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the period. State of Alaska Department of Revenue bought a new stake in OptimizeRx in the fourth quarter valued at about $62,000. Aaron Wealth Advisors LLC bought a new stake in OptimizeRx in the first quarter valued at about $66,000. Finally, Hsbc Holdings PLC bought a new position in OptimizeRx during the first quarter worth about $85,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.